- Home
- LIPO vs TOVX Comparison
LIPO vs TOVX Comparison
Compare LIPO & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- TOVX
- Stock Information
- Founded
- LIPO 2005
- TOVX 2001
- Country
- LIPO United States
- TOVX United States
- Employees
- LIPO N/A
- TOVX N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LIPO Health Care
- TOVX Health Care
- Exchange
- LIPO Nasdaq
- TOVX Nasdaq
- Market Cap
- LIPO 3.8M
- TOVX 3.2M
- IPO Year
- LIPO 2022
- TOVX 2006
- Fundamental
- Price
- LIPO $2.85
- TOVX $1.48
- Analyst Decision
- LIPO Strong Buy
- TOVX Strong Buy
- Analyst Count
- LIPO 1
- TOVX 1
- Target Price
- LIPO $16.00
- TOVX $6.00
- AVG Volume (30 Days)
- LIPO 91.5K
- TOVX 1.2M
- Earning Date
- LIPO 02-25-2025
- TOVX 11-12-2024
- Dividend Yield
- LIPO N/A
- TOVX N/A
- EPS Growth
- LIPO N/A
- TOVX N/A
- EPS
- LIPO N/A
- TOVX N/A
- Revenue
- LIPO $483,533.00
- TOVX N/A
- Revenue This Year
- LIPO N/A
- TOVX N/A
- Revenue Next Year
- LIPO N/A
- TOVX N/A
- P/E Ratio
- LIPO N/A
- TOVX N/A
- Revenue Growth
- LIPO 0.78
- TOVX N/A
- 52 Week Low
- LIPO $2.21
- TOVX $1.14
- 52 Week High
- LIPO $12.00
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- LIPO 45.72
- TOVX 49.48
- Support Level
- LIPO $2.78
- TOVX $1.42
- Resistance Level
- LIPO $3.17
- TOVX $2.03
- Average True Range (ATR)
- LIPO 0.29
- TOVX 0.17
- MACD
- LIPO -0.04
- TOVX -0.01
- Stochastic Oscillator
- LIPO 7.61
- TOVX 12.70
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.